StockData

Adlai Nortye vs Kyntra Bio

ANL and KYNB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANL and KYNB compare

Kyntra Bio keeps more of each dollar of sales as profit, with a net margin of 3968% compared with −711% at Adlai Nortye.

Kyntra Bio scores higher on the StockData Score (5 against 0 for Adlai Nortye), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANLKYNB
Size and price
Market cap–$8.3M
Share price$9.48$2.04
Change, 1 year508%−76.5%
Change, 5 years–−99.3%
Beta (5Y)3.902.01
Employees–34
StockData Score
Total score05 (better)
Valuation score02 (better)
Growth score00
Performance score02 (better)
Health score01 (better)
Dividend score00
Valuation
P/E–0.0×
P/S–1.8×
FCF yield–−461%
Growth
Revenue growth (TTM)–−37.1%
Revenue growth, 5Y average–−48.4%
Profitability
Gross margin–6.3%
Operating margin−714% (better)−1090%
Net margin−711%3968% (better)
FCF margin−673% (better)−824%
Financial health
Interest coverage−23.3×−5.4× (better)
Current ratio0.652.69 (better)
Altman Z-score–−24.50
Piotroski F-score15 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions22.1%24.7%
Held by insiders14.7%15.7%
Insider net buying, 12 months−$411K$39.7K (better)
Short interest, % of float–2.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.